broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K15600710-066-05-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 3.244995 | 0.338552 | 0.21043 | 1 | 5.264536 | null | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000978 |
BRD-K16730910-001-10-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.998654 | -0.163619 | -0.003723 | 0.999014 | 49.051987 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000978 |
BRD-K17555800-003-02-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.739629 | 2.007271 | 0.224458 | 0.973924 | 4.083946 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000978 |
BRD-K17610631-001-03-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.861633 | -3.697836 | 0.147433 | 0.900145 | 0.650208 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000978 |
BRD-K17743125-001-08-4 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.379386 | 0.635532 | 0.419237 | 1 | 4.845663 | null | belinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9 | hematologic malignancy | peripheral T-cell lymphoma (PTCL) | ONC(=O)\C=C\c1cccc(c1)S(=O)(=O)Nc1ccccc1 | Launched | true | ACH-000978 |
BRD-K17894950-001-14-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.936503 | 5.808212 | 0.141462 | 0.977107 | 0.302299 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000978 |
BRD-K18961567-001-01-1 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.746896 | -0.83863 | 0.103008 | 0.842094 | 0.273132 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000978 |
BRD-K19540840-001-09-4 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 44.045587 | 0.886117 | -0.156386 | 1 | 52,583,715.197652 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000978 |
BRD-K19687926-001-04-1 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.990873 | -0.359287 | -0.109001 | 0.993836 | 0.957679 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000978 |
BRD-K19796430-001-05-6 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.959536 | 0.196998 | 0.010996 | 0.97629 | 0.011758 | null | sonidegib | smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1, C[C@H]1CN(C[C@@H](C)O1)c1ccc(NC(=O)c2cccc(-c3ccc(OC(F)(F)F)cc3)c2C)cn1 | Launched | true | ACH-000978 |
BRD-K22064724-001-01-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.25468 | 5.359177 | 0.578064 | 0.920795 | 3.568035 | 4.07506 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000978 |
BRD-K22822991-001-02-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.001587 | -0.181538 | -0.042988 | 1 | 0.004554 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000978 |
BRD-K23228615-001-02-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.749144 | 2.556652 | 0.00068 | 0.95537 | 1.787433 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000978 |
BRD-K23984367-001-07-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 4.119613 | 2.311227 | 0.459065 | 1 | 12.092977 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000978 |
BRD-K26026438-001-01-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.770444 | 0.494771 | 0.170428 | 0.90462 | 0.210101 | null | tucatinib | EGFR inhibitor | ERBB2 | null | null | Cc1cc(Nc2ncnc3ccc(NC4=NC(C)(C)CO4)cc23)ccc1Oc1ccn2ncnc2c1 | Phase 2 | true | ACH-000978 |
BRD-K26657438-001-15-2 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.877835 | 0.192556 | -0.049709 | 0.935764 | 0.043943 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000978 |
BRD-K28822270-001-03-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.866717 | -3.387799 | -0.029371 | 0.955132 | 0.016754 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000978 |
BRD-K29905972-001-06-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.881696 | 6.128105 | 0.097895 | 0.940717 | 0.07727 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000978 |
BRD-K30577245-001-05-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.463366 | 2.215887 | 0.639818 | 1 | 0.003213 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000978 |
BRD-K31698212-001-02-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.049588 | -0.358127 | -0.153839 | 1 | 0.132298 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000978 |
BRD-K31928526-001-02-1 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.194034 | 0.228142 | -0.005963 | 1 | 0.111242 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000978 |
BRD-K33379087-001-07-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.814343 | -8.123306 | 0.010092 | 0.85508 | 1.189082 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000978 |
BRD-K33610132-001-02-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.0194 | -0.256943 | -0.006601 | 1 | 0.107479 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000978 |
BRD-K33622447-066-01-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.284234 | -0.170359 | -0.114623 | 1 | 0.007289 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000978 |
BRD-K35520305-001-16-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.906445 | -3.33685 | 0.311645 | 0.952461 | 0.084518 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000978 |
BRD-K36627727-001-05-4 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.057151 | 0.075974 | -0.010917 | 1 | 0.006497 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000978 |
BRD-K36788280-001-01-2 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.885986 | -1.74675 | 0.143289 | 0.941721 | 0.087042 | null | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000978 |
BRD-K37379014-001-02-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.783967 | 4.20518 | 0.805707 | 1 | 0.003713 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000978 |
BRD-K38332599-001-01-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.780238 | 0.545101 | -0.033564 | 0.819579 | 0.000963 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000978 |
BRD-K38527262-300-01-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.845131 | -1.708469 | 0.025986 | 0.920078 | 0.04111 | null | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000978 |
BRD-K38852836-001-02-1 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.627359 | 4.398376 | 0.409066 | 1 | 0.014274 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000978 |
BRD-K39974922-001-04-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.862143 | -0.07855 | -0.05544 | 0.93129 | 0.071978 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000978 |
BRD-K41859756-001-06-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.144196 | 3.242977 | 0.56684 | 1 | 0.006444 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000978 |
BRD-K42495768-001-01-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.798976 | -0.17945 | -0.182809 | 0.894355 | 0.143045 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000978 |
BRD-K42805893-001-04-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.044846 | -0.009875 | -0.008048 | 1 | 8,722,794,678.068502 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000978 |
BRD-K42828737-001-03-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.923749 | 3.692923 | 0.017474 | 0.934916 | 0.002523 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000978 |
BRD-K42898655-001-01-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.014712 | -0.07645 | -0.075295 | 1 | 756,958.422618 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000978 |
BRD-K44227013-001-06-4 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.941058 | 0.565846 | -0.126355 | 0.970663 | 0.080092 | null | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000978 |
BRD-K44408410-001-17-6 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.958481 | -2.392911 | 0.003093 | 0.96742 | 1.241152 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000978 |
BRD-K44827188-001-06-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.624717 | 0.853273 | -0.003744 | 0.889309 | 0.633405 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000978 |
BRD-K46386702-001-02-1 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.775462 | -0.437985 | 0.202451 | 0.891619 | 0.063077 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000978 |
BRD-K49328571-001-15-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.683472 | 0.521947 | 0.254839 | 1 | 1.687696 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000978 |
BRD-K49350383-001-14-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.59965 | 0.949065 | 0.841884 | 1 | 0.398615 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000978 |
BRD-K50010139-001-01-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.849031 | -0.055471 | -0.015269 | 1 | 0.001153 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000978 |
BRD-K50168500-001-07-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.774232 | 0.059242 | 0.021629 | 0.89547 | 0.97094 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000978 |
BRD-K51313569-001-07-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.253981 | -0.023582 | -0.027028 | 1 | 491,406,061,348,107,000 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000978 |
BRD-K51791723-003-01-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.463419 | 0.314858 | 0.141807 | 0.737096 | 0.090872 | null | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000978 |
BRD-K51967704-001-03-6 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.295296 | 0.2513 | 0.212923 | 1 | 47.171864 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000978 |
BRD-K52313696-001-12-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.924771 | 0.026639 | -0.001967 | 0.96534 | 29.000928 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000978 |
BRD-K53414658-001-08-2 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.97948 | 0.055719 | -0.029056 | 0.988879 | 0.003743 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000978 |
BRD-K53972329-001-07-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.038336 | -0.250223 | -0.022968 | 1 | 0.40536 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000978 |
BRD-K54256913-001-08-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.00577 | 0.221266 | 0.000001 | 1 | 0.000926 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000978 |
BRD-K54955827-001-02-2 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.100948 | -0.186437 | -0.123063 | 1 | 237.109032 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000978 |
BRD-K54997624-001-06-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.808518 | 1.26802 | 0.216347 | 0.917104 | 0.150226 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000978 |
BRD-K55187425-236-05-2 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.724424 | 10.334246 | 0.731508 | 1 | 0.147472 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000978 |
BRD-K56343971-001-14-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.99888 | -0.186791 | -0.068377 | 0.99933 | 0.749897 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000978 |
BRD-K56981171-001-02-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.980829 | -1.284051 | -0.093632 | 0.988767 | 0.180568 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000978 |
BRD-K57080016-001-15-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.686864 | -1.982466 | 0.0471 | 0.942136 | 0.003612 | null | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000978 |
BRD-K57169635-001-04-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.75536 | 0.897244 | -0.116485 | 0.876674 | 0.074969 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000978 |
BRD-K58435339-001-03-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.744627 | -10.428487 | 0.073924 | 0.908759 | 0.019551 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000978 |
BRD-K58529924-001-01-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.840299 | -0.981679 | -0.061345 | 0.876487 | 1.331006 | null | ONC201 | AKT inhibitor, MAP kinase inhibitor | TNFSF10 | null | null | Cc1ccccc1CN1C2=NCCN2C2=C(CN(Cc3ccccc3)CC2)C1=O | Phase 2 | true | ACH-000978 |
BRD-K58550667-001-08-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.323328 | 2.159444 | 0.606025 | 0.728171 | 0.012668 | 0.020509 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000978 |
BRD-K59317601-001-05-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.742235 | 0.015174 | -0.041859 | 0.872659 | 0.37818 | null | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000978 |
BRD-K59369769-001-22-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.910466 | -3.41255 | -0.158656 | 0.967648 | 0.020336 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000978 |
BRD-K60866521-001-07-1 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.262 | 0.743376 | 0.157547 | 1 | 0.039682 | null | idelalisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC[C@H](Nc1ncnc2[nH]cnc12)c1nc2cccc(F)c2c(=O)n1-c1ccccc1 | Launched | true | ACH-000978 |
BRD-K60997853-001-02-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.877462 | -0.023823 | -0.01855 | 0.925681 | 6,134,383.307252 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000978 |
BRD-K61192372-001-08-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.817914 | -4.20196 | 0.31812 | 0.857053 | 1.241868 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000978 |
BRD-K62008436-001-23-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.541842 | 2.778626 | 0.508619 | 1 | 0.001085 | null | paclitaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TLR4, TUBB, TUBB1 | oncology | ovarian cancer, breast cancer, non-small cell lung cancer (NSCLC) | CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1, CC(=O)O[C@@H]1C2=C(C)[C@H](C[C@@](O)([C@@H](OC(=O)c3ccccc3)[C@@H]3[C@@]4(CO[C@@H]4C[C@H](O)[C@@]3(C)C1=O)OC(C)=O)C2(C)C)OC(=O)[C@H](O)[C@@H](NC(=O)c1ccccc1)c1ccccc1 | Launched | true | ACH-000978 |
BRD-K62196610-001-01-6 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.776139 | -6.368255 | -0.076372 | 0.890156 | 0.071349 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000978 |
BRD-K62200014-003-10-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.053088 | 0.206967 | -0.027942 | 1 | 0.026029 | null | anagrelide | phosphodiesterase inhibitor | PDE3A | hematology, hematologic malignancy | thrombocythemia, myeloproliferative neoplasms | Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl, Clc1ccc2N=C3NC(=O)CN3Cc2c1Cl | Launched | true | ACH-000978 |
BRD-K62391742-001-09-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.797474 | -2.056788 | 0.247764 | 0.862642 | 0.440725 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000978 |
BRD-K62627508-001-01-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.047643 | -0.252567 | -0.181414 | 1 | 1.455391 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000978 |
BRD-K63504947-001-14-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.344347 | 0.879277 | -0.107395 | 1 | 0.276662 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000978 |
BRD-K63712959-001-01-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.893342 | -0.924156 | 0.005401 | 0.981684 | 0.002489 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000978 |
BRD-K64052750-001-22-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.883124 | -7.194704 | 0.03475 | 0.92553 | 0.295664 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000978 |
BRD-K64881305-001-03-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.739655 | 2.792416 | 0.560977 | 1 | 0.015496 | null | ispinesib | kinesin inhibitor | KIF11 | null | null | CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1, CC(C)[C@@H](N(CCCN)C(=O)c1ccc(C)cc1)c1nc2cc(Cl)ccc2c(=O)n1Cc1ccccc1 | Phase 2 | true | ACH-000978 |
BRD-K66175015-001-12-4 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.248973 | -0.676562 | 0.066063 | 1 | 0.313502 | null | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000978 |
BRD-K67844266-003-01-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.884087 | -3.879898 | -0.058934 | 0.942319 | 0.076319 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000978 |
BRD-K69001009-001-02-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.860064 | -0.197296 | -0.127851 | 0.926989 | 0.125501 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000978 |
BRD-K69694239-001-02-2 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.241054 | 0.577141 | 0.371772 | 0.694138 | 0.22781 | 0.712368 | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000978 |
BRD-K69776681-001-03-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.519824 | 3.219966 | 0.827729 | 1 | 0.016031 | null | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000978 |
BRD-K70301465-001-05-9 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.411306 | 0.410762 | 0.125096 | 1 | 0.170382 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000978 |
BRD-K70401845-001-15-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.225926 | -0.03784 | -0.015975 | 1 | 0.227158 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000978 |
BRD-K73838513-003-05-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.944295 | -1.303124 | -0.113567 | 0.946113 | 16.745329 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000978 |
BRD-K75009076-001-02-1 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | -0.03648 | 2.687703 | 0.383849 | 0.963997 | 8.654808 | 8.431126 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000978 |
BRD-K76210423-001-01-6 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.091791 | -0.134761 | -0.041906 | 1 | 0.170465 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000978 |
BRD-K76239644-001-02-6 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.818994 | -4.18956 | 0.21666 | 0.903825 | 0.105863 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000978 |
BRD-K76674262-001-03-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.63098 | 4.558474 | 0.339501 | 0.799807 | 0.051706 | null | homoharringtonine | protein synthesis inhibitor | RPL3 | hematologic malignancy | chronic myeloid leukemia (CML) | COC(=O)C[C@](O)(CCCC(C)(C)O)C(=O)O[C@H]1[C@H]2c3cc4OCOc4cc3CCN3CCC[C@]23C=C1OC | Launched | true | ACH-000978 |
BRD-K76908866-001-07-6 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.898173 | 2.111504 | 0.311121 | 0.910567 | 0.001908 | null | CP-724714 | EGFR inhibitor, protein tyrosine kinase inhibitor | ERBB2 | null | null | COCC(=O)NC\C=C\c1ccc2ncnc(Nc3ccc(Oc4ccc(C)nc4)c(C)c3)c2c1 | Phase 2 | true | ACH-000978 |
BRD-K77625799-001-07-7 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.881919 | -0.532899 | 0.248421 | 0.930408 | 0.215509 | null | vandetanib | EGFR inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | EGFR, EPHA1, EPHA10, EPHA2, EPHA3, EPHA4, EPHA5, EPHA6, EPHA7, EPHA8, EPHB1, EPHB2, EPHB3, EPHB4, EPHB6, ERBB2, ERBB3, ERBB4, FLT1, FLT4, KDR, PTK6, RET, SRC, TEK, VEGFA | oncology | medullary thyroid cancer (MTC) | COc1cc2c(Nc3ccc(Br)cc3F)ncnc2cc1OCC1CCN(C)CC1 | Launched | true | ACH-000978 |
BRD-K78431006-001-15-1 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.28968 | -0.507884 | -0.105063 | 1 | 0.001914 | null | crizotinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl, C[C@@H](Oc1cc(cnc1N)-c1cnn(c1)C1CCNCC1)c1c(Cl)ccc(F)c1Cl | Launched | true | ACH-000978 |
BRD-K79254416-001-21-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.78472 | -1.000346 | -0.222537 | 0.962045 | 0.002767 | null | decitabine | DNA methyltransferase inhibitor | DNMT1, DNMT3A | hematologic malignancy, hematology | myelodysplastic diseases (MDS), anemia, chronic myeloid leukemia (CML) | Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1, Nc1ncn([C@H]2C[C@H](O)[C@@H](CO)O2)c(=O)n1 | Launched | true | ACH-000978 |
BRD-K81016934-001-02-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.188899 | -0.386472 | 0.057016 | 1 | 0.007624 | null | INC-280 | c-Met inhibitor | MET | null | null | CNC(=O)c1ccc(cc1F)-c1cnc2ncc(Cc3ccc4ncccc4c3)n2n1 | Phase 2 | true | ACH-000978 |
BRD-K81418486-001-44-2 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.864634 | -5.309695 | -0.151141 | 0.903239 | 0.628112 | null | vorinostat | HDAC inhibitor | HDAC1, HDAC10, HDAC11, HDAC2, HDAC3, HDAC5, HDAC6, HDAC8, HDAC9 | hematologic malignancy | cutaneous T-cell lymphoma (CTCL) | ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1, ONC(=O)CCCCCCC(=O)Nc1ccccc1 | Launched | true | ACH-000978 |
BRD-K81473043-001-19-5 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.706918 | -1.376808 | 0.005465 | 0.910246 | 0.000735 | null | tanespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCC=C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 3 | true | ACH-000978 |
BRD-K82135108-001-04-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.789577 | 1.31817 | 0.186043 | 0.883316 | 0.007097 | null | elesclomol | oxidative stress inducer | HSPA1A | null | null | CN(NC(=O)CC(=O)NN(C)C(=S)c1ccccc1)C(=S)c1ccccc1 | Phase 3 | true | ACH-000978 |
BRD-K82746043-001-19-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.888528 | -0.711184 | -0.362898 | 0.948217 | 0.054114 | null | navitoclax | BCL inhibitor | BCL2, BCL2L1, BCL2L2 | null | null | CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1, CC1(C)CCC(=C(CN2CCN(CC2)c2ccc(cc2)C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c(c2)S(=O)(=O)C(F)(F)F)C1)c1ccc(Cl)cc1 | Phase 2 | true | ACH-000978 |
BRD-K82818427-001-04-8 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 1.680736 | 0.291543 | -0.066067 | 1 | 0.535169 | null | batimastat | matrix metalloprotease inhibitor | ADAM28, ADAMTS5, MMP12, MMP16, MMP2, MMP8 | null | null | CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO, CNC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)[C@H](CSc1cccs1)C(=O)NO | Phase 3 | true | ACH-000978 |
BRD-K83029223-001-01-3 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 2.138148 | 0.80497 | 0.459627 | 1 | 0.037047 | null | litronesib | kinesin-like spindle protein inhibitor | KIF11 | null | null | CCNCCS(=O)(=O)NC[C@]1(SC(NC(=O)C(C)(C)C)=NN1C(=O)C(C)(C)C)c1ccccc1 | Phase 2 | true | ACH-000978 |
BRD-K83988098-001-02-0 | ACH-000978 | EN_ENDOMETRIUM | MTS010 | 1 | 0.70274 | -0.118515 | 0.000042 | 0.826571 | 0.022582 | null | alvespimycin | HSP inhibitor | HSP90AA1 | null | null | CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O, CO[C@H]1C[C@H](C)CC2=C(NCCN(C)C)C(=O)C=C(NC(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@H]1O)C2=O | Phase 2 | true | ACH-000978 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.